Biochemical Engineering
Adaptimmune's TCR T-cell therapy clears efficacy bar in rare cancers
12th November 2021
Adaptimmune Therapeutics is on track to bring the first engineered T-cell therapy to market in a solid tumor indication. With the response rate above the target threshold at the interim analysis, the biotech is certain the study will hit its primary endpoint and deliver the data needed to seek approval next year. Source: Fierce Biotech 12/11/2021
Back to group news